<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354133</url>
  </required_header>
  <id_info>
    <org_study_id>A 121/06</org_study_id>
    <nct_id>NCT00354133</nct_id>
  </id_info>
  <brief_title>Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's Disease</brief_title>
  <acronym>EARLYSTIM</acronym>
  <official_title>The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Parkinson Study Group (GPS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Schleswig-Holstein</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assistance Publique - HÃ´pitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KKS Netzwerk</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Parkinson Study Group (GPS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlystim Study: Patients are randomized either to medical treatment or subthalamic
      stimulation. The observation period was 2 years. The primary outcome criterium: PDQ-39.

      Post study Follow up studies: After the 24 months observation period also BMT patients could
      be operated and all patients will be observed for 10 years or longer to elucidate whether
      earlier stimulation has advantages (or drawbacks) compared to later stimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinsons' disease is one of the most disabling chronic neurological diseases. It can be
      treated sufficiently until motor complications with fluctuations of mobility and dyskinesias
      develop. The quality of life and the social and occupational functioning is relentlessly
      deteriorating with longer disease duration once the complications of conservative therapy
      develop. High-frequency stimulation of the subthalamic nucleus especially improves the motor
      complications of Parkinson's disease and preliminary data suggest that also the quality of
      life and psychosocial handicap are improved. So far this therapy is only used for patients
      which have already undergone personal, professional and social degradation due to motor
      complications of the disease. The aim of this study is to assess the use of this therapy in
      earlier stages of the disease, when motor complications have just developed and before
      patients are significantly affected in their social and occupational functioning.

      The main study (Earlystim) was finished in March 2012 and published in February 2013
      (Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early
      motor complications. N Engl J Med. Feb 14 2013;368(7):610-622.) Patients, who were treated
      with BMT only in the Earlystim Study were privileged to be operated after the 24 months and a
      follow up phase of 5 years was planned to elucidate whether earlier stimulation has
      advantages (or drawbacks) compared to later stimulation.

      As operated patients fare better in terms of quality of life and other outcomes (see
      publication), it will be important to know if patients who are operated earlier keep an
      advantage in all thoses parameters over those who were operated later or if those operated
      later will catch up after surgery. Also the pattern of adverse events among earlier and later
      operated patients may differ. These issues can be addressed with the post-study follow-up
      (PSFU) studies of the patients of the Earlystim trial. The results of these investigations
      elucidate longterm issues of DBS in PD and may affect the recommendations of surgery for
      patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PDQ-39</measure>
    <time_frame>24 months</time_frame>
    <description>Difference in the PDQ-39 summary index at 24 months compared to the baseline assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS part III</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the Unified Parkinson's disease Rating Scale (UPDRS) part III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS II scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the UPDRS II scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency, type and severity of therapy related adverse events of medication or DBS, Change in medication (L-DOPA equivalents)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UPDRS VI scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the UPDRS VI scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SCOPA-PS</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the SCOPA-PS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDI scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the BDI scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the MADRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BPRS scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the BPRS scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mattis Dementia Scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the Mattis Dementia Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ardouin Behaviour Scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the Ardouin Behaviour Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Starkstein-Apathy Scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the Starkstein-Apathy Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>professional Fitness scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the professional Fitness scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 scale</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the SF-36 scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain (VAS) scale,</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the pain (VAS) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical global impression (CGI-GI) scale</measure>
    <time_frame>24 months</time_frame>
    <description>change in the clinical global impression (CGI-GI) scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;best&quot;-state</measure>
    <time_frame>24 months</time_frame>
    <description>Change in the number of hours per day in the &quot;best&quot;-state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>&quot;best&quot; state dyskinesias</measure>
    <time_frame>24 months</time_frame>
    <description>Frequency and severity of &quot;best&quot; state dyskinesias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping-hours per day</measure>
    <time_frame>24 months</time_frame>
    <description>Sleeping-hours per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gait</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in gait</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Speech</measure>
    <time_frame>24 months</time_frame>
    <description>Changes in speech</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>DBS treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm are treated with Deep Brain Stimulation (DBS) of the Nucleus subthalamicus with the device Kinetra and Soletra (neurostimulator, Medtronic) and addtionally get best medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMT treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm get best medical treatment only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kinetra and Soletra (neurostimulator, Medtronic)</intervention_name>
    <description>Patients in this arm were implanted with a neurostimulator (Kinetra and Soletra from Medtronic) are stimulated. Additionally the get best medical treatment.</description>
    <arm_group_label>DBS treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Best Medical Treatment</intervention_name>
    <description>Patients in this arm get best medical treatment only</description>
    <arm_group_label>BMT treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease

          -  Hoehn and Yahr stage â¤ 2.5 in the best &quot;on&quot;med condition

          -  Disease duration &gt; 4 years

          -  Presence of fluctuations and/or dyskinesias for no more than 3 years

          -  One of the two following forms of impairment:

          -  Impairment in activities of daily living (UPDRS II &gt; 6) due to PD-symptoms despite
             medical treatment in the &quot;worst&quot; condition or

          -  Impairment of social and occupational functioning (measured with a modified SOFAS) due
             to PD-symptoms despite medical treatment (51-80%)

          -  PDQ-39 completed

          -  Written informed consent

          -  For the patients in France a social security number is required

        Exclusion Criteria

          -  Major depression with suicidal thoughts (Beck Depression Inventory &gt; 25)

          -  Dementia (Mattis Score â¤ 130)

          -  Acute psychosis

          -  Need for nursing care

          -  Any medical or psychological problems which may interfere with a smooth conduction of
             the study protocol (e.g. cancer with a limited life expectancy)

          -  Drug or alcohol addiction

          -  Surgical contraindications

          -  Fertile women not using adequate contraceptive methods

          -  Women who are pregnant or breast feeding

          -  Illiteracy or insufficient language skills (German or French) to complete the
             questionnaires

          -  Simultaneous participation in another clinical trial except that other trial does not
             affect the Earlystim study as approved and documented by the steering committee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenther Deuschl, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Christian-Albrechts-University Kiel, Schittenhelmstr. 10, D 24105 Kiel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Vidailhet, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier PitiÃ©- SalpÃªtriÃ¨re, FÃ©dÃ©ration des Maladies du SystÃ¨me Nerveux, 47-83 Boulevard de lÂ´HÃ´pital, F- 75651 Paris Cedex 13</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Michallon Hospital, CHU Grenoble, Service de Neurologie, BP217</name>
      <address>
        <city>Grenoble Cedex</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Neurologie C, HÃ´pital Neurologique et neurochirurgical Pierre Wertheimer , 59 Bd Pinel 69677 BRON Cedex</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier La Timone, Service de neurologie et pathologie du mouvement,Boulevard Jean Moulin</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;HÃ´pital Nord LaÃ«nnec Boulevard Jacques-Monod - Saint-Herblain</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIC, CHU PitiÃ©-SalpÃªtriÃ¨re, 47-83 Bd de l'HÃ´pital</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital La MilÃ©trie, Tour Jean Bernard, 350 Av Jacques CÅur, BP 577</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalo-Universitaire de Rouen, Charles Nicolle, bat. DV, 1 rue de Germont</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation Clinique, Pavillon Riser, HÃ´pital Purpan,Place du Dr Baylac TSA 40031</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fÃ¼r Neurologie, Charite</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik der UniversitÃ¤t, Moorenstr. 5</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische UniversitÃ¤tsklinik Freiburg, Breisacher Str. 64</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paracelsus-Elena-Klinik, Kassel, Klinikstrasse 16</name>
      <address>
        <city>Kassel</city>
        <zip>34128</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fÃ¼r Neurologie, UniversitÃ¤tsklinikum Schleswig-Holstein, Schittenhelmstr. 10</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fÃ¼r Neurologie</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der UniversitÃ¤t MÃ¼nchen Neurologische Klinik und Poliklinik - GroÃhadern, Marchioninistr. 15</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum TÃ¼bingen, Klinik fÃ¼r Neurochirurgie, Hoppe-Seyler-Str.3</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kompetenznetz-parkinson.de/</url>
    <description>(German Research Collaboration, funded by the German Ministry of Research)</description>
  </link>
  <link>
    <url>http://www.kks.uni-marburg.de/</url>
    <description>(Homepage Coordination Center for Clinical Studies to STN Study, Language: German)</description>
  </link>
  <link>
    <url>http://www.kks.uni-marburg.de/</url>
    <description>Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. Feb 14 2013;368(7):610-622.</description>
  </link>
  <results_reference>
    <citation>Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, HÃ¤lbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, MaltÃªte D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, KrÃ¼ger R, Pinsker MO, Amtage F, RÃ©gis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158.</citation>
    <PMID>23406026</PMID>
  </results_reference>
  <results_reference>
    <citation>Deuschl G, Schade-Brittinger C, Agid Y; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 May 23;368(21):2038. doi: 10.1056/NEJMc1303485.</citation>
    <PMID>23697520</PMID>
  </results_reference>
  <results_reference>
    <citation>Dams J, Balzer-Geldsetzer M, Siebert U, Deuschl G, Schuepbach WM, Krack P, Timmermann L, Schnitzler A, Reese JP, Dodel R; EARLYSTIM-investigators. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications. Mov Disord. 2016 Aug;31(8):1183-91. doi: 10.1002/mds.26740.</citation>
    <PMID>27506638</PMID>
  </results_reference>
  <results_reference>
    <citation>LhommÃ©e E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, HÃ¤lbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-DÃ¶ring F, Kupsch A, KrÃ¼ger R, Elben S, ChabardÃ¨s S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, MaltÃªte D, Sauvaget A, Rau J, Schnitzler A, SchÃ¼pbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P; EARLYSTIM study group. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial. Lancet Neurol. 2018 Mar;17(3):223-231. doi: 10.1016/S1474-4422(18)30035-8.</citation>
    <PMID>29452685</PMID>
  </results_reference>
  <results_reference>
    <citation>SchÃ¼pbach WM, Rau J, Houeto JL, Krack P, Schnitzler A, Schade-Brittinger C, Timmermann L, Deuschl G. Myths and facts about the EARLYSTIM study. Mov Disord. 2014 Dec;29(14):1742-50. doi: 10.1002/mds.26080. Epub 2014 Nov 14. Review.</citation>
    <PMID>25399678</PMID>
  </results_reference>
  <results_reference>
    <citation>Deuschl G, SchÃ¼pbach M, Knudsen K, Pinsker MO, Cornu P, Rau J, Agid Y, Schade-Brittinger C. Stimulation of the subthalamic nucleus at an earlier disease stage of Parkinson's disease: concept and standards of the EARLYSTIM-study. Parkinsonism Relat Disord. 2013 Jan;19(1):56-61. doi: 10.1016/j.parkreldis.2012.07.004. Epub 2012 Jul 28.</citation>
    <PMID>22841616</PMID>
  </results_reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <last_update_submitted>June 22, 2018</last_update_submitted>
  <last_update_submitted_qc>June 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Deep Brain Stimulation</keyword>
  <keyword>PDQ-39</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>by inidividual contact with the Coordinatin Investigator Prof.Dr. Deuschl</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

